Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116505405 | 11650540 | 5 | F | 20160906 | 20151021 | 20160912 | EXP | PHHY2015BR123723 | NOVARTIS | 0.00 | M | Y | 86.00000 | KG | 20160912 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116505405 | 11650540 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 10 MG, QMO | 21008 | 10 | MG | SUSPENSION | /month | ||||||
| 116505405 | 11650540 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, QMO | 21008 | 20 | MG | SUSPENSION | /month | ||||||
| 116505405 | 11650540 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO | 21008 | 30 | MG | SUSPENSION | /month | ||||||
| 116505405 | 11650540 | 4 | C | SOMAVERT | PEGVISOMANT | 1 | Unknown | UNK | U | 0 | |||||||||
| 116505405 | 11650540 | 5 | C | CARBAMAZEPINE. | CARBAMAZEPINE | 1 | Oral | 3 DF, QD | 0 | 3 | DF | TABLET | QD | ||||||
| 116505405 | 11650540 | 6 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 1 DF, QD (1 TABLET A DAY) | 0 | 1 | DF | TABLET | QD | ||||||
| 116505405 | 11650540 | 7 | C | GLIFAGE | METFORMIN HYDROCHLORIDE | 1 | Oral | 2 DF, QD (500 MG, 2 TABLETS A DAY) | 0 | 2 | DF | TABLET | QD | ||||||
| 116505405 | 11650540 | 8 | C | AMITRIPTYLINE HYDROCHLORIDE. | AMITRIPTYLINE HYDROCHLORIDE | 1 | Oral | 1 DF, QD | 0 | 1 | DF | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116505405 | 11650540 | 1 | Acromegaly |
| 116505405 | 11650540 | 4 | Product used for unknown indication |
| 116505405 | 11650540 | 5 | Trigeminal neuralgia |
| 116505405 | 11650540 | 6 | Product used for unknown indication |
| 116505405 | 11650540 | 7 | Diabetes mellitus |
| 116505405 | 11650540 | 8 | Trigeminal neuralgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116505405 | 11650540 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116505405 | 11650540 | Ear pain | |
| 116505405 | 11650540 | Eye pain | |
| 116505405 | 11650540 | Headache | |
| 116505405 | 11650540 | Immunodeficiency | |
| 116505405 | 11650540 | Influenza | |
| 116505405 | 11650540 | Neoplasm progression | |
| 116505405 | 11650540 | Pain | |
| 116505405 | 11650540 | Pain in jaw | |
| 116505405 | 11650540 | Rhinalgia | |
| 116505405 | 11650540 | Sleep disorder due to a general medical condition |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 116505405 | 11650540 | 1 | 2009 | 0 | ||
| 116505405 | 11650540 | 2 | 2010 | 0 | ||
| 116505405 | 11650540 | 3 | 2013 | 0 | ||
| 116505405 | 11650540 | 5 | 2009 | 0 | ||
| 116505405 | 11650540 | 7 | 2011 | 0 | ||
| 116505405 | 11650540 | 8 | 2009 | 0 |